Innovacell Secures U.S. Clearance for Global Phase III Cell Therapy Clinical Trial
MT Newswires Live
Jul 02
Innovacell received regulatory clearance from the U.S. FDA to include American clinical sites and patients in its ongoing Phase III global clinical trial, according to a Tokyo bourse filing on Thursday.
The study evaluates ICEF15, an advanced cell therapy candidate designed as a less invasive, potentially curative treatment for patients suffering from urge fecal incontinence.
The placebo-controlled trial is already actively enrolling patients across Japan and 11 European countries to evaluate the treatment's long-term efficacy and safety.
With the majority of the global enrollment target already met, the company has begun preparing multiple U.S. sites to help finalize patient recruitment by the end of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.